Omicral (Itraconazole)

Itraconazole, the active ingredient in Omicral, is an azole antifungal presented as a 100 mg capsule for oral use. It treats systemic fungal infections such as aspergillosis and candidiasis in immunocompromised patients. GNH USA supplies Omicral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

GNH USA supplies Omicral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Omicral (itraconazole) is an azole antifungal that acts on invasive fungal disease pathways.

- Aspergillosis: Reduces fungal burden and improves survival in invasive pulmonary aspergillosis. - Candidiasis: Treats systemic candidemia and deep‑tissue candidiasis. - Histoplasmosis: Controls infection in disseminated histoplasmosis. - Blastomycosis: Clears fungal lesions in blastomycosis. - Sporotrichosis: Improves outcomes for cutaneous and disseminated sporotrichosis.

Adverse reactions to itraconazole vary in frequency and severity.

Common Side Effects: - Nausea: Mild to moderate stomach upset. - Headache: Transient headache reported by some patients. - Diarrhea: Loose stools occurring during therapy. - Abdominal pain: Cramping or discomfort in the abdomen. - Rash: Mild skin erythema or itching. - Elevated liver enzymes: Mild, reversible increases in hepatic transaminases.

Serious or Rare Side Effects: - Hepatotoxicity: Clinically significant liver injury, potentially leading to jaundice. - Congestive heart failure: Worsening of pre‑existing cardiac failure. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Visual disturbances: Blurred vision or photophobia. - QT prolongation: Cardiac rhythm changes detectable on ECG. - Anaphylaxis: Immediate hypersensitivity reaction requiring emergency care.

When prescribing itraconazole, clinicians should consider several safety measures.

- Liver function monitoring: Check baseline enzymes and repeat during therapy. - Cardiac assessment: Evaluate for history of heart failure before use. - Drug‑interaction review: Identify concomitant medications that affect CYP3A4. - Pregnancy and lactation: Avoid use unless benefits outweigh risks. - Renal impairment: Adjust monitoring in patients with severe kidney disease. - Store at ambient temperature: Keep below 25 °C, in original packaging, protected from moisture.

Itraconazole interacts with many medicines through CYP3A4 inhibition and other pathways.

Major Interactions (Avoid): - Simvastatin: Increased risk of rhabdomyolysis. - Midazolam: Potentiated sedation and respiratory depression. - Quinidine: Elevated quinidine levels leading to arrhythmias. - Ritonavir: Marked increase in itraconazole exposure. - Cisapride: Risk of serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Warfarin: Enhanced anticoagulant effect, monitor INR. - Phenytoin: Reduced itraconazole levels, may require dose adjustment. - Ketoconazole: Additive hepatotoxic potential. - Digoxin: Slight increase in serum digoxin concentrations. - Rifampicin: Decreased itraconazole efficacy due to enzyme induction.